- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04165278
Effects of Hyperthermic Baths on Motor Symptoms of Parkinson's Disease
December 24, 2020 updated by: Nanjing First Hospital, Nanjing Medical University
The aim of this study is to further evaluate the effects of seasonal variation and the aquatic thermal environment of hyperthermic baths (HTB) on the Motor Symptoms (MS) of Parkinson's Disease (PD), and whether the environmental temperature is associated with these effects.
Study Overview
Detailed Description
After being informed about the study and potential risks, all participants will give written informed consent.
All participants who meet the inclusion criteria will undergo a complete history and physical examination, including an assessment using the Movement Disorder Society-United Parkinson's Disease Rating Scale (MDS-UPDRS), H&Y stage, MMSE and MOCA.
Each participant will receive two subjective measures (the Movement Disorder Society-United Parkinson's Disease Rating Scale part III motor examination total scores and the modified Webster Symptoms Score) nine times in an open medication state (open state).
Each participant will take hyperthermic baths (HTB) at the same time on the first, third and fifth days.
The participants will receive subjective measures before and after the HTB.
The time at which the subjective measures begin after the HTB will be recorded.
In the second week, no participants accept any intervention.
To avoid the effects of fluctuations in dopaminergic drugs concentrations, subjective measures will be given without HTB at the recorded times on the fifteenth, seventeenth and nineteenth days.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Yingdong Zhang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥ 18 years of age
- Diagnosis of Idiopathic Parkinson's Disease(IPD)based on the Movement Disorder Society clinical diagnostic criteria for Parkinson's Disease
- Subjective feeling that Motor Symptoms(MS)of Parkinson's Disease (PD) were affected by seasonal variation (i.e., MS were more severe in winter than in summer) and improved after HTB
- No change in the patient's PD medication regimen during the study
Exclusion Criteria:
- Symptomatic bradycardia, severe postural hypotension, symptomatic coronary insufficiency, severe organic heart damage, severe cerebrovascular disease, and active psychosis
- Dementia (Mini-Mental State Examination (MMSE) < 24 and Montreal Cognitive Assessment (MOCA) < 26)
- Failure to cooperate with the study requirements and poor compliance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Hyperthermic baths
On the first, third and fifth day of the first week, each subject will take the Hyperthermic Baths (HTB) at the same time.
They will receive subjective measures before and after HTB.
In the second week, no subjects accepted any intervention.
On the fifteenth, seventeenth and nineteenth days of the third week, these subjects will receive two subjective measures without HTB in the same environment and scoring time as the experimental group.
|
Taking hyperthermic baths
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Influence of Hyperthermic Baths on Motor Symptoms as Assessed by the MDS-UPDRS Part III Motor Examination Total Scores Rating Scale
Time Frame: 3 week
|
The minimum and maximum values of Movement Disorder Society - United Parkinson's Disease Rating Scale (MDS-UPDRS) part III motor examination total scores are 0 and 132 respectively, and higher scores mean a worse outcome.
|
3 week
|
|
The Influence of Hyperthermic Baths on Motor Symptoms as Assessed by the Modified Webster Symptoms Score
Time Frame: 3 week
|
The minimum and maximum values of Modified Webster Symptoms Score are 0 and 30 respectively, and higher scores mean a worse outcome.
|
3 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Yingdong Zhang, PhD, Nanjing Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 1, 2018
Primary Completion (ACTUAL)
October 18, 2019
Study Completion (ACTUAL)
October 18, 2019
Study Registration Dates
First Submitted
November 14, 2019
First Submitted That Met QC Criteria
November 14, 2019
First Posted (ACTUAL)
November 15, 2019
Study Record Updates
Last Update Posted (ACTUAL)
December 29, 2020
Last Update Submitted That Met QC Criteria
December 24, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY20190926-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
we'll share our study design and the study results with other researchers
IPD Sharing Time Frame
the data will become available 12 months after the study finished for 1 year
IPD Sharing Access Criteria
clinical doctors
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.